Delhi High Court Allows Dr. Reddy's to Export Semaglutide, Challenges Novo Nordisk Patent Validity
核心洞察
Delhi High Court ruled that Dr. Reddy's Laboratories can manufacture and export semaglutide after finding Novo Nordisk's patent prima facie invalid.
The court allowed exports to countries where Novo Nordisk lacks patent protection, while domestic sales remain prohibited until March 2026.
The ruling is expected to boost confidence among Indian companies entering the Rs 850 crore obesity (搜索) market and accelerate generic competition.
Delhi High Court delivered a landmark ruling allowing Dr. Reddy's Laboratories to manufacture and export semaglutide, the active ingredient in blockbuster weight loss drugs, after determining that Novo Nordisk's patent is prima facie invalid. The decision is expected to reshape the competitive landscape in India's Rs 850 crore obesity (搜索) market and accelerate generic competition globally.
Court Finds Patent Challenge Credible
Justice Manmeet Pritam Singh Arora ruled that Dr. Reddy's had established a prima facie credible challenge against Novo Nordisk's patent for semaglutide during a hearing on Tuesday. The court specifically allowed Dr. Reddy's and OneSource Speciality Pharma (搜索) to export products containing semaglutide to countries where Novo Nordisk does not enjoy patent protection.
The ruling came in response to an injunction petition filed by the Danish pharmaceutical company seeking to block Dr. Reddy's manufacturing activities for the weight-loss drug semaglutide, which Novo Nordisk sells under the brand name Wegovy.
Patent Landscape and Legal Arguments
Novo Nordisk's primary consumption patent for semaglutide expired in September 2024, but the company still holds a secondary patent in India relating to the manufacturing process and delivery mechanism of the drug, which remains valid until March 2026. Currently, Novo Nordisk sells Wegovy and Rybelsus using its patent on semaglutide and has received Central Drugs Standard Control Organisation approval for Ozempic.
Dr. Reddy's received regulatory approval to manufacture semaglutide in December 2024 and began production in April. Novo Nordisk subsequently filed a permanent injunction suit, arguing that Dr. Reddy's and OneSource Speciality imported semaglutide active pharmaceutical ingredient and produced finished formulations without permission, thereby infringing its patent.
Defense Against Evergreening Claims
In their defense, Dr. Reddy's and OneSource Speciality argued that Novo Nordisk's patent lacked novelty and represented an attempt at evergreening to extend exclusivity beyond the expiry of the primary patent. The Indian companies emphasized that they hold licenses from the Central Drugs Standard Control Organisation to manufacture semaglutide but have no approval to sell it within India.
Dr. Reddy's and OneSource Speciality stated that their current production is solely for export to countries where Novo Nordisk's patent rights have expired. They cited exemptions in the Patents Act that protect certain forms of manufacture and export undertaken for regulatory purposes or for lawful commercial supply in markets where the patent does not apply.
Market Impact and Industry Response
The case is being closely watched across the pharmaceutical industry as it could accelerate generic competition, ease supply constraints, and reshape sourcing strategies for obesity (搜索) and diabetes (搜索) therapies across global markets. With semaglutide's patent expiry due in March next year, momentum is building in India as companies prepare to launch generics, potentially widening access across price-sensitive segments.
Recently, Novo Nordisk reduced Wegovy's price by 37% and partnered with Emcure Pharma (搜索) to expand its reach using the Pune-based company's distribution channel and field force. These moves come as the company faces competition from Eli Lilly's Mounjaro, which has emerged as the number one brand in the domestic pharmaceutical retail market.
Market Response
Following the court ruling, Dr. Reddy's Laboratories shares ended 1.2% higher at INR 1,275.20, while OneSource Speciality Pharma (搜索) shares closed 0.9% higher at INR 1,627.00. A Novo Nordisk spokesperson declined to comment on the matter, stating the company was awaiting the certified copy of the order.
The ruling represents a significant development in the blockbuster weight loss drug space and is expected to boost confidence among domestic companies pursuing plans to enter the high-growth obesity (搜索) market.